3 Reasons to Sell Gilead Sciences Now
Gilead Sciences (NASDAQ: GILD) is a veritable monster in the pharmaceutical industry. Thanks to its industry-leading entry into the coronavirus market this year with its antiviral treatment, remdesivir, Gilead has been a favorite stock for speculative and more critical healthcare investors alike. And, with its compelling collection of potentially curative drugs for diseases like HIV in development, it's hard to see how Gilead could suffer from a serious stumble.
On the other hand, there are several headwinds that may prevent Gilead's stock from growing as rapidly as its investors might like. The company has already shrunk in value this year, and its prospects for next year may be even dimmer. While Gilead will probably recover from the ongoing turbulence, skittish investors should consider these three reasons to sell their shares in Gilead right now.
Image source: Getty Images.
Source Fool.com
